Caxton Associates (New York)’s Ligand Pharmaceuticals LGND Stock Holding History

Caxton Associates (New York)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,250	Closed	-$1.3M	–	528
2023 Q4	$1.3M	Buy	+18,250	New	+$1.08M	0.07%	190
2020 Q3	–	Sell	-10,174	Closed	-$710K	–	427
2020 Q2	$710K	Buy	10,174 +4,924	+94%	+$312K	0.06%	89
2020 Q1	$238K	Buy	+5,250	New	+$298K	0.04%	304
2018 Q4	–	Sell	-4,963	Closed	-$850K	–	389
2018 Q3	$850K	Sell	4,963 -1,196	-19%	-$180K	0.06%	165
2018 Q2	$796K	Sell	6,159 -264	-4%	-$29.5K	0.04%	195
2018 Q1	$662K	Buy	+6,423	New	+$635K	0.03%	238

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s LGND Position: Q1 2024 in Review

Caxton Associates (New York) sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 18,250 shares — an estimated $1.3M sold.

Caxton Associates (New York) first reported a position in LGND in Q1 2018 and held it in 6 quarters. The position peaked at $1.3M in Q4 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

Caxton Associates (New York) reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Caxton Associates (New York) sold 18,250 Ligand Pharmaceuticals shares in Q1 2024, an estimated $1.3M.
Caxton Associates (New York) first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Caxton Associates (New York)'s Ligand Pharmaceuticals position peaked at $1.3M in Q4 2023.
222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Caxton Associates (New York)'s 13F filing for Q1 2024, filed 15 May 2024.